Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study

Trial Profile

Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Jan 2018

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease
  • Focus Therapeutic Use
  • Acronyms Direct III
  • Sponsors Svelte Medical Systems
  • Most Recent Events

    • 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 12 Oct 2016 Planned End Date changed from 1 Feb 2018 to 1 Sep 2018.
    • 12 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top